CELLINK has been granted a patent for its unique intelligent printhead bioprinting technology enabling our bioprinting users to easily exchange and utilize their printhead and toolhead technology of choice to meet their evolving needs. The patent protection applies to the Swedish market. The company also conducts the process of expanding patent protection in additional countries.
The patent protection (SE 542653) from the Swedish Patent and Registration Office (PRV) shows uniqueness and height of innovation. The intelligent and exchangeable printhead technology is used in CELLINK’s BIO X bioprinting platform, BIO X and BIO X6 – designed to be the most flexible bioprinting platform for printing complex tissue structures.
For bioprinting applications that require multiple cells and use of bioinks with various temperature and resolution demands, the BIO X bioprinting platform is the most versatile bioprinter equipped with intelligent and exchangeable printheads, enabling our users to easily select the printhead or toolhead they need: Heated Pneumatic Printhead, Thermoplastic Printhead, Temperature-controlled Pneumatic Printhead, Electromagnetic Droplet Printhead, Syringe Pump Printhead, Photo-curing Tool Head and HD Camera Tool Head.
“Our team at CELLINK is excited and thrilled to have this patent granted for our revolutionary intelligent-printhead and bioprinting technology. We are certain that these innovations, in the hands of our customers, will continue to pave the way for the future of medicine.” – Dr. Héctor Martínez, CTO
The granted patent strengthens the company's protection for intellectual properties and complements a full portfolio of bioprinting solutions being developed at CELLINK.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.